2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162663
    VU0448088 1417616-42-2 98.67%
    VU0448088 (ML253) is a potent and cross the blood-brain barrier tricyclic muscarinic acetylcholine receptor subtype 4 (M4) positive allosteric modulator with EC50 values of 56, 176 nM for human and rat, respectively. VU0448088 has the potential for the research of psychotic.
    VU0448088
  • HY-162675
    COB-187 1862177-86-3
    COB-187 is a potent, ATP-competitive and selective inhibitor of GSK-3β. COB-187 inhibits GSK-3 through a reversible and Cysteine (Cys)-199-dependent mechanism. COB-187 inhibits LPS induced cytokine production and SARS-CoV-2 spike protein-induced CXCL10 production.
    COB-187
  • HY-163018
    Kv3.1 modulator 2 98%
    Kv3.1 modulator 2 (compound 4) is a Kv3.1 channels modulator with an EC50 value of 68 nM.
    Kv3.1 modulator 2
  • HY-163384
    (S)-CE-123 2378384-49-5 98%
    (S)-CE-123 is a potent, selective, and novel atypical dopamine transporter (DAT) inhibitor with an EC50 of 2.76 μM in uptake inhibition assays conducted in HEK293 cells stably expressing human isoforms of DAT. (S)-CE-123, a Modafinil analogue, is able to penetrate the blood–brain barrier. (S)-CE-123 improves cognitive and motivational processes in experimental animals.
    (S)-CE-123
  • HY-16346S
    Netupitant-d6 2070015-31-3 ≥98.0%
    Netupitant-d6 is the deuterium labeled Netupitant (CID-6451149), which is a highly potent and selective, orally active neurokinin-1 (NK1) receptor antagonist.
    Netupitant-d6
  • HY-163575
    TDP-43-IN-2 3033951-93-5 98.52%
    TDP-43-IN-2 (compound 17) is a TDP-43 inhibitor, and can be used for study of neurodegenerative disease.
    TDP-43-IN-2
  • HY-163855
    KGP-25
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia.
    KGP-25
  • HY-164580
    RO3244794 361457-01-4 99.64%
    RO3244794 is a potent and selective IP (prostacyclin) receptor antagonist, with a pKi of 7.7 and 6.9 in human platelet and recombinant IP receptor system, respectively. RO3244794 exhibits analgesic and anti-inflammatory potential.
    RO3244794
  • HY-16489A
    Terodiline hydrochloride 7082-21-5 99.78%
    Terodiline hydrochloride is an M1-selective muscarinic receptor (mAChR) antagonist with Kbs of 15, 160, 280, and 198 nM in rabbit vas deferens (M1), atria (M2), bladder (M3) and ileal muscle (M3), respectively. Terodiline hydrochloride also is a Ca2+ blocker. Terodiline hydrochloride acts as a treatment for urinary frequency and urge incontinence.
    Terodiline hydrochloride
  • HY-16637A
    Folic acid sodium 6484-89-5 98%
    Folic acid (Vitamin B9) sodium is a orally active essential nutrient from the B complex group of vitamins. Folic acid sodium shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid sodium can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency.
    Folic acid sodium
  • HY-16765A
    Axelopran sulfate 949904-50-1 98%
    Axelopran sulfate is an opioid receptor antagonist with pKi values of 9.8, 8.8 and 9.9 for human recombinant μ and δ receptors and guinea pig κ receptor, respectively.
    Axelopran sulfate
  • HY-167739
    (S,S)-Dehydroemetine 2649-50-5 98%
    (S,S)-Dehydroemetine is an antispasmodic compound with inhibitory activity on smooth muscle. (S,S)-Dehydroemetine can be used to inhibit diseases related to smooth muscle contraction.
    (S,S)-Dehydroemetine
  • HY-167745
    DDR1-IN-9 1934246-20-4 99.64%
    DDR1-IN-9 is a selective inhibitor of DDR1 with significant kinase activity suppression, exhibiting a Kd value of 4.7 nM and an IC50 value of 9.4 nM. DDR1-IN-9 demonstrates reduced potency against a diverse panel of 400 nonmutated kinases, indicating its specificity. Additionally, DDR1-IN-9 shows favorable pharmacokinetic properties and potential therapeutic effects in a model of pulmonary fibrosis.
    DDR1-IN-9
  • HY-167830
    SDM-8 2242777-37-1 99.79%
    SDM-8 is a difluoro-analog of UCB-J (HY-136873).SDM-8 shows high SV2A binding affinity with a Ki of 0.58 nM. SDM-8 can be used in the study of Alzheimer's disease.
    SDM-8
  • HY-169004
    CBT-295 99.34%
    CBT-295 is an orally active autotaxin (ATX) inhibitor. CBT-295 exhibits a significant reduction in inflammatory cytokines like TGF-β, TNF-α and IL-6 levels, also reduced bile duct proliferation marker CK-19 and lowered liver fibrosis. The reversal of liver fibrosis with CBT-295 led to a reduction in blood and brain ammonia levels. CBT-295 also reduced neuroinflammation induced by ammonia. CBT-295 is promising for research of liver cirrhosis and associated encephalopathy.
    CBT-295
  • HY-169460
    6-Methoxy DMT 2426-88-2 98.2%
    6-Methoxy DMT (6-MeO-DMT) is derivative of N,N-dimethyltryptamine (HY-110062) that is a non-hallucinogenic compound.
    6-Methoxy DMT
  • HY-170589
    GPR17 antagonist 1 1574405-61-0 98%
    GPR17 antagonist 1 (compound 978) is a GPR17 antagonist. GPR17 antagonist 1 can be used in the study of diabetes and obesity.
    GPR17 antagonist 1
  • HY-171328
    RG-15 1076189-55-3
    RG-15 is the orally active antagonist for dopamine receptor that exhibits goof affinity to human D2 receptor and human D3 receptor with pKi of 8.23 and 10.49. RG-15 inhibits dopamine-stimulated [35S]GTPγS binding with IC50 of 21.2 nM (rat striatal membranes), 36.7 nM (mouse A9 cells expressing human D2L receptors) and 7.2 nM (CHO cells expressing human D3 receptors). RG-15 increases the turnover and biosynthesis of dopamine in mouse striatum and olfactory bulb, exhibiting antipsychotic activity.
    RG-15
  • HY-172182
    ONO-2920632 2230296-66-7 99.11%
    ONO-2920632 is an orally active and central nervous system (CNS)-penetrant TREK activator, with EC50 values of 0.3 µM and 2.8 μM for TREK-1 and TREK-2, respectively. ONO-2920632 exhibits selectivity for other K2P channels (>91-fold selective versus TASK1, TASK2, TASK3, TRAAK, and TWIK2; 31-fold selective versus TRESK). ONO-2920632 possesses analgesic effects and can be used in research on pain, migraine, and neurological disorders.
    ONO-2920632
  • HY-172420
    Bretisilocin 2698331-35-8 98%
    Bretisilocin is the agonist for 5-HT2A receptor and exhibits antidepressant activity.
    Bretisilocin
Cat. No. Product Name / Synonyms Application Reactivity